July 2025 in “Dermatology and Therapy” This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review reports that alopecia, particularly alopecia areata, significantly impacts mental health and quality of life through stress and immune mechanisms, with treatments like Janus kinase inhibitors showing promise for improving both hair regrowth and psychological well-being.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review found significant psychosocial impacts of alopecia, noting that those with alopecia, particularly alopecia areata, experience higher rates of depression and anxiety. The review also highlighted new treatments like Janus kinase inhibitors that improve both hair regrowth and quality of life.
September 2024 in “International Journal of Women’s Dermatology” This study emphasizes that for effective management of alopecic sarcoidosis, evidence-based strategies including prompt diagnosis and systemic evaluation, particularly for scarring alopecia, are crucial to achieve better patient outcomes.
This article discusses the management of pediatric alopecia areata in children aged 6 to 11, emphasizing the need for psychosocial support and limited medical treatments, as no systemic therapies are FDA-approved for this age group, despite the significant psychosocial burden.
